Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
A 2-part, multicenter, Phase 2/3, randomized, double-blind, placebo-controlled, parallel
group study to evaluate the safety and efficacy of upamostat in adult patients with COVID-19
disease who do not require inpatient care.